Idera Pharmaceuticals To Provide Multiple Presentations On Intratumoral IMO-2125 At The 2016 Society For Immunotherapy Of Cancer (SITC) Annual Meeting

CAMBRIDGE, Mass. and EXTON, Pa., Nov. 09, 2016 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), a clinical-stage biopharmaceutical company developing toll-like receptor and RNA therapeutics for patients with cancer and rare diseases, today announced that new data from the Phase 1/2 clinical trial for intratumoral IMO-2125, a TLR9 agonist, being evaluated for the treatment of late-stage metastatic melanoma, will be presented at the 2016 Society for Immunotherapy of Cancer (SITC) Annual Meeting in National Harbor, MD, November 9-13, 2016.

Oral Presentations

Date: Wednesday, November 9, 2016, Presentation Time: 11:15 AM E.T.Session Title: Clinical New Agents in DevelopmentPresentation Title:  IMO-2125, An Investigational Intratumoral Toll-Like Receptor 9 Agonist, Modulates the Tumor Microenvironment to Enhance Anti-Tumor ActivityPresenter: Mark J. Cornfeld, M.D. M.P.H., Vice President, Oncology Medical Lead, Idera PharmaceuticalsLocation: Gaylord National Hotel & Convention Center, Cherry Blossom Ballroom

Date: Friday, November 11, 2016, Presentation Time: 3:15 PM E.T.Session Title: State of the Art Immunotherapies: Challenges and OpportunitiesPresentation Title: Reactivating the anti-tumor immune response by targeting innate and adaptive immunity in a phase I/II study of intratumoral IMO-2125 in combination with systemic ipilimumab in patients with anti-PD-1 refractory metastatic melanomaPresenter: Presenter: Cara Haymaker, Ph.D., Instructor, The University of Texas MD Anderson Cancer CenterLocation: Gaylord National Hotel & Convention Center, Maryland Ballroom

Poster Presentation Date: Saturday, November 12, 2016: Presentation Time: 11:45 AM E.T. - 1:00 PM E.T.Session Title:  ImmunotherapyPoster Number: 216Presentation Title: Reactivating the anti-tumor immune response by targeting innate and adaptive immunity in a phase I/II study of intratumoral IMO-2125 in combination with systemic ipilimumab in patients with anti-PD-1 refractory metastatic melanomaPresenter: Cara Haymaker, Ph.D., Instructor, The University of Texas MD Anderson Cancer CenterLocation: Gaylord National Hotel & Convention Center, Prince George's Exhibition Hall AB

A copy of the slides from Dr. Cornfeld's presentation will be made available on Idera's corporate website at http://www.iderapharma.com/our-approach/key-publications/ on Wednesday, November 9 at 11:15 AM E.T.  Copies of Dr. Haymaker's presentation and related poster will be also be made available on Idera's corporate website on Friday, November 11 at 3:15 PM E.T., in accordance with the embargo policies set forth by SITC.

"As we noted in late September, we are extremely excited by the initial clinical outcomes we have generated with intratumoral IMO-2125, in combination with ipilimumab," stated Joanna Horobin, M.B., Ch.B., Idera's Chief Medical Officer.  "The translational data from this trial is adding to our understanding of how IMO-2125 positively modulates the tumor microenvironment and enabling previously cold tumors an opportunity for regression and ultimately successful outcomes for patients.  The translational research from this trial is critical to further this understanding as well as to help guide the direction of IMO-2125's development."

If you liked this article you might like

Achillion Shares Are Plunging on Termination of Hepatitis C Pact

5 Stocks Insiders Love Right Now

8 Biotech Stocks Under $10 Making Big Moves Higher

5 Stocks Ready for Breakouts

Trade-Ideas: Idera Pharmaceuticals (IDRA) Is Today's Weak On High Relative Volume Stock